Infamous Alzheimer APOE gene ;
95% of the time, a combination of genetics is needed badly environment and unhealthy life style to trigger Alzheimer’s disease. However, a gene called apolipoprotein E (APOE) can make a big difference. Learn more.
Researchers have not found a specific gene that directly causes late-onset form of the disease. However, a genetic risk factor that has a form of apolipoprotein E (APOE) gene on chromosome 19 which increases the risk of a person.
APOE comes in several different forms, or alleles
ε4 APOE gene is called a risk factor because it increases the risk of developing the disease a person. However, the legacy of an APOE ε4 allele definitely does not mean a person developing Alzheimer’s disease. Some people with APOE ε4 allele never get the disease, and other people who develop Alzheimer’s disease have no APOE e4 alleles.
A method called whole genome sequencing determined the entire DNA sequence of the genome of an individual at one time.
Using a relatively new approach called around the association study (GWAS) , genome researchers have identified a number of ROIs in the genome (set of a whole organism DNA, including all its genes) that may increase a person’s risk for late-onset Alzheimer’s disease in varying degrees. 2015, had confirmed 33 regions of interest in the genome of Alzheimer.
A blood test can determine which APOE alleles a person has, but the results can not predict who will or will not develop Alzheimer’s disease. It is unlikely that genetic testing ever be able to predict the disease with 100 percent accuracy, researchers believe, because too many other factors can influence its development and progression.
Currently, APOE testing is used in research settings to identify study participants who may be at increased risk of developing Alzheimer’s disease. This knowledge helps scientists look for changes in the brain in the first participants and compare the effectiveness of treatments for people with different profiles of APOE. Most researchers believe that APOE testing is useful to study the risk of Alzheimer’s disease in large groups of people, but not to determine the risk of a particular person.
Genetic testing is used by researchers conducting Clinical trials and by doctors to help diagnose the disease early onset Alzheimer’s. However, genetic testing is not recommended otherwise.
National Institute on Aging supports several major genetic research programs.
Volunteers are essential for genetic research of Alzheimer’s disease. The genetic information that researchers can collect and analyze individuals and families in both healthy volunteers and those who may be at risk -the more clues that will search for new genes risk factors.
For more information on genetic studies of Alzheimer’s disease, contact the toll free number 1-800-526-2839 NCRAD or http://ncrad.iu.edu visit.
to learn more about volunteering for clinical trials and studies of Alzheimer’s disease, visit www.nia.nih.gov/alzheimers/volunteer.
This article was originally published on alzheimersweekly, Read the original article here